Ovid Therapeutics Inc. – NASDAQ:OVID
Ovid Therapeutics stock price today
$0.931
-0.03
-4.04%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Ovid Therapeutics stock price monthly change
+1.74%
month
Ovid Therapeutics stock price quarterly change
+1.74%
quarter
Ovid Therapeutics stock price yearly change
-71.47%
year
Ovid Therapeutics key metrics
Market Cap | 69.74M |
Enterprise value | 164.63M |
P/E | -3.61 |
EV/Sales | 109.55 |
EV/EBITDA | -3.12 |
Price/Sales | 128.40 |
Price/Book | 1.45 |
PEG ratio | 0.02 |
EPS | -0.73 |
Revenue | 473.53K |
EBITDA | -60.47M |
Income | -50.67M |
Revenue Q/Q | 123.70% |
Revenue Y/Y | 283.29% |
Profit margin | -3604.66% |
Oper. margin | -3696.4% |
Gross margin | 0% |
EBIT margin | -3696.4% |
EBITDA margin | -12770.17% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOvid Therapeutics stock price history
Ovid Therapeutics stock forecast
Ovid Therapeutics financial statements
| Jun 2023 | 75K | -12.40M | -16544.44% |
|---|---|---|---|
| Sep 2023 | 108.97K | -11.25M | -10325.94% |
| Dec 2023 | 141.56K | -15.32M | -10823.55% |
| Mar 2024 | 148K | -11.69M | -7901.35% |
| Mar 2024 | 148K | -11.69M | -7901.35% |
|---|---|---|---|
| Sep 2025 | 5.71M | -12.13M | -212.33% |
| Oct 2025 | 87K | -14.82M | -17038.71% |
| Dec 2025 | 80.75K | -14.21M | -17604.36% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 136229764 | 25.53M | 18.74% |
|---|---|---|---|
| Sep 2023 | 125028691 | 23.73M | 18.99% |
| Dec 2023 | 144026783 | 56.22M | 39.04% |
| Mar 2024 | 131613000 | 53.33M | 40.52% |
| Jun 2023 | -11.70M | 20.06M | 211.09K |
|---|---|---|---|
| Sep 2023 | -10.05M | -4.35M | 223.71K |
| Dec 2023 | -11.91M | -48.51M | 30.03M |
| Mar 2024 | -16.68M | 20.18M | 228K |
Ovid Therapeutics alternative data
| Aug 2023 | 46 |
|---|---|
| Sep 2023 | 40 |
| Oct 2023 | 40 |
| Nov 2023 | 40 |
| Dec 2023 | 39 |
| Jan 2024 | 39 |
| Feb 2024 | 39 |
| Mar 2024 | 40 |
| Apr 2024 | 40 |
| May 2024 | 40 |
| Jun 2024 | 40 |
| Jul 2024 | 40 |
Ovid Therapeutics other data
24.98%
-29.77%
of OVID is owned by hedge funds
35
-24
17.59M
-20.96M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 18248 | 0 |
| Patent |
|---|
Application Filling date: 19 Apr 2022 Issue date: 4 Aug 2022 |
Grant Filling date: 18 Dec 2020 Issue date: 21 Jun 2022 |
Application Filling date: 21 Dec 2021 Issue date: 14 Apr 2022 |
Grant Filling date: 8 Oct 2020 Issue date: 5 Apr 2022 |
Grant Filling date: 29 Jun 2018 Issue date: 22 Mar 2022 |
Application Filling date: 21 Oct 2021 Issue date: 10 Feb 2022 |
Application Filling date: 30 Sep 2021 Issue date: 20 Jan 2022 |
Application Filling date: 18 Aug 2021 Issue date: 9 Dec 2021 |
Application Filling date: 12 Aug 2021 Issue date: 2 Dec 2021 |
Grant Filling date: 7 Jul 2020 Issue date: 28 Sep 2021 |
| Insider | Compensation |
|---|---|
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir (1953) Pres, Chief Executive Officer & Chairman | $861,240 |
| Mr. Thomas Michael Perone J.D., M.B.A. (1965) Gen. Counsel, Chief Compliance Officer & Corporation Sec. | $633,370 |
| Mr. Jeffrey A. Rona (1968) Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer | $494,500 |
-
What's the price of Ovid Therapeutics stock today?
One share of Ovid Therapeutics stock can currently be purchased for approximately $0.93.
-
When is Ovid Therapeutics's next earnings date?
Unfortunately, Ovid Therapeutics's (OVID) next earnings date is currently unknown.
-
Does Ovid Therapeutics pay dividends?
No, Ovid Therapeutics does not pay dividends.
-
How much money does Ovid Therapeutics make?
Ovid Therapeutics has a market capitalization of 69.74M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 73.93% to 391.7K US dollars.
-
What is Ovid Therapeutics's stock symbol?
Ovid Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "OVID".
-
What is Ovid Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ovid Therapeutics?
Shares of Ovid Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ovid Therapeutics's key executives?
Ovid Therapeutics's management team includes the following people:
- Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir Pres, Chief Executive Officer & Chairman(age: 72, pay: $861,240)
- Mr. Thomas Michael Perone J.D., M.B.A. Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 60, pay: $633,370)
- Mr. Jeffrey A. Rona Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer(age: 57, pay: $494,500)
-
How many employees does Ovid Therapeutics have?
As Jul 2024, Ovid Therapeutics employs 40 workers.
-
When Ovid Therapeutics went public?
Ovid Therapeutics Inc. is publicly traded company for more then 8 years since IPO on 5 May 2017.
-
What is Ovid Therapeutics's official website?
The official website for Ovid Therapeutics is ovidrx.com.
-
Where are Ovid Therapeutics's headquarters?
Ovid Therapeutics is headquartered at 1460 Broadway, New York, NY.
-
How can i contact Ovid Therapeutics?
Ovid Therapeutics's mailing address is 1460 Broadway, New York, NY and company can be reached via phone at +64 6 661 7661.
Ovid Therapeutics company profile:
Ovid Therapeutics Inc.
ovidrx.comExchange:
NASDAQ
Full time employees:
25
Industry:
Biotechnology
Sector:
Healthcare
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
1460 Broadway
New York, NY 10036
New York, NY 10036
CIK: 0001636651
ISIN: US6904691010
CUSIP: 690469101
